Hybrid Protein Developed as Tools for Gene Cutting, Editing
|
By LabMedica International staff writers Posted on 23 Sep 2010 |
A U.S. team of researchers has developed a kind of hybrid proteins that can make double-strand DNA breaks at specific sites in living cells, potentially leading to better gene replacement and gene editing therapies.
Dr. Bing Yang, assistant professor of genetics, development and cell biology at Iowa State University (ISU; Ames, USA;), and his colleagues developed the hybrid protein by joining parts of two different bacterial proteins. One is called a TAL (transcription activator-like) effector, which functions to find the specific site on the gene that needs to be cut, and the other is an enzyme called a nuclease that cuts the DNA strands. Dr. Yang hopes this study will lead to the ability to engineer genomes by cutting out defective or undesirable parts of DNA, or by replacing defective or undesirable gene segments with a functioning piece of replacement DNA--a process called homologous recombination.
Dr. Yang reported that these hybrid proteins could be constructed to locate specific segments of the DNA in any sort of organism. "This breakthrough could eventually make it possible to efficiently modify plant, animal and even human genomes,” said Dr. Yang. "It should be effective in a range of organisms.”
The proteins function by binding onto the specific segment of DNA the researcher needs to change. These proteins do this by reading the DNA sequence and finding the specific area to be cut. Once the protein binds onto the DNA at the correct spot, the other half of the protein then cuts the double-stranded DNA. Bad or undesirable DNA can be resected and good or more desirable DNA can be introduced. When the DNA heals, the good DNA is included in the gene.
Dr. Yang began his project approximately one year ago after seeing the results of research by Dr. Adam Bogdanove, ISU associate professor of plant pathology, showing that TAL effectors use a very clear-cut code to bind to a specific DNA sequence. This discovery allowed Dr. Yang to predict precisely where the TAL effector nuclease will bind on the DNA to make the cut. Another study had similar results.
The conecept has also been validated by Dr. Bogdanove and Dr. Dan Voytas, collaborator in genetics, development, and cell biology at Iowa State, and director of the Center for Genome Engineering at the University of Minnesota (Twin Cities, USA). The TAL effector-nuclease approach improves on tools currently available for genome modification. It should be faster and less expensive to make TAL effector nucleases, and simpler to design them to recognize specific DNA sequences, according to Dr. Yang.
Yang's findings appeared in August 2010 in the online version of the journal Nucleic Acids Research. Dr. Voytas' and Bogdanove's study also appeared in August 2010 the journal Genetics. Dr. Voytas and Dr. Bogdanove were also able to demonstrate that the TAL effector part of the hybrid protein can be modified to target new DNA sequences.
Related Links:
Iowa State University
Dr. Bing Yang, assistant professor of genetics, development and cell biology at Iowa State University (ISU; Ames, USA;), and his colleagues developed the hybrid protein by joining parts of two different bacterial proteins. One is called a TAL (transcription activator-like) effector, which functions to find the specific site on the gene that needs to be cut, and the other is an enzyme called a nuclease that cuts the DNA strands. Dr. Yang hopes this study will lead to the ability to engineer genomes by cutting out defective or undesirable parts of DNA, or by replacing defective or undesirable gene segments with a functioning piece of replacement DNA--a process called homologous recombination.
Dr. Yang reported that these hybrid proteins could be constructed to locate specific segments of the DNA in any sort of organism. "This breakthrough could eventually make it possible to efficiently modify plant, animal and even human genomes,” said Dr. Yang. "It should be effective in a range of organisms.”
The proteins function by binding onto the specific segment of DNA the researcher needs to change. These proteins do this by reading the DNA sequence and finding the specific area to be cut. Once the protein binds onto the DNA at the correct spot, the other half of the protein then cuts the double-stranded DNA. Bad or undesirable DNA can be resected and good or more desirable DNA can be introduced. When the DNA heals, the good DNA is included in the gene.
Dr. Yang began his project approximately one year ago after seeing the results of research by Dr. Adam Bogdanove, ISU associate professor of plant pathology, showing that TAL effectors use a very clear-cut code to bind to a specific DNA sequence. This discovery allowed Dr. Yang to predict precisely where the TAL effector nuclease will bind on the DNA to make the cut. Another study had similar results.
The conecept has also been validated by Dr. Bogdanove and Dr. Dan Voytas, collaborator in genetics, development, and cell biology at Iowa State, and director of the Center for Genome Engineering at the University of Minnesota (Twin Cities, USA). The TAL effector-nuclease approach improves on tools currently available for genome modification. It should be faster and less expensive to make TAL effector nucleases, and simpler to design them to recognize specific DNA sequences, according to Dr. Yang.
Yang's findings appeared in August 2010 in the online version of the journal Nucleic Acids Research. Dr. Voytas' and Bogdanove's study also appeared in August 2010 the journal Genetics. Dr. Voytas and Dr. Bogdanove were also able to demonstrate that the TAL effector part of the hybrid protein can be modified to target new DNA sequences.
Related Links:
Iowa State University
Latest BioResearch News
- Genetic Study Links Inherited Blindness to Gene Tied to Rare Metabolic Disorder
- Population-Scale Proteomics Study Identifies New Genetic-Protein Links
- Circulating Tumor DNA Helps Identify Targets for Personalized Immunotherapy
- Researchers Classify 108 Lysosomal Disorders in Updated Diagnostic Framework
- New Autoantibody Target Identified in Neuromyelitis Optica Spectrum Disorder
- New Immune Target Could Support More Precise High Blood Pressure Treatment
- New Gene-Disease Link May Help Diagnose Rare Neurodevelopmental Disorders
- Researchers Identify Shared Molecular Networks Behind Fatigue-Related Illnesses
- Blood Metabolite Signature Predicts ALS Progression and Points to Treatment Strategy
- Whole-Blood Extracellular Vesicle Analysis Captures Molecular Signals Missed by Plasma Testing
- Age-Related Genomic Differences Could Refine Treatment Decisions in Lung Cancer
- Computational Tool Identifies Central Asthma Genes for Target Discovery
- Molecular Pathway Reveals Driver of Triple-Negative Breast Cancer Spread
- D-Serine May Predict Immune Checkpoint Therapy Resistance in Gastric Cancer
- New Genetic Cause Identified for Neurodevelopmental Disorder
- New Genetic Discovery Could Support Precision Diabetes Care
Channels
Clinical Chemistry
view channel
Blood Biomarker Detects Alzheimer’s Changes Decades Before Symptoms in Down Syndrome
Alzheimer’s disease can begin altering the brain long before clinical symptoms appear, creating a challenge for early-stage detection and research. People with Down syndrome face a particularly high age-related... Read more
Study Questions Broad Fasting Requirements Before Routine Blood Tests
Routine blood testing is central to diagnosis, monitoring, and disease risk assessment. Many patients are still asked to fast for 8–12 hours before phlebotomy, even though the requirement was originally... Read more
Elevated Lipoprotein(a) Linked to Long-Term Progression of Carotid Atherosclerosis
Lipoprotein(a), or Lp(a), is a genetically determined blood lipid and an important risk factor for cardiovascular disease. Its relationship to long-term carotid atherosclerosis has remained unclear, particularly... Read moreMolecular Diagnostics
view channel
Genomic Screening Expands Detection of Treatable Conditions in Newborns
Conventional newborn screening can miss conditions that lack biochemical biomarkers or present atypically. Initial hearing screens may also fail to detect hearing loss that is later identified through... Read more
Age-Based Genetic Testing May Miss Most Inherited Cancer Risk Variants
Inherited cancer risk can influence diagnosis, treatment planning, and family screening, yet current testing practices often depend on a patient’s age at diagnosis. Many patients undergo germline genetic... Read more
New NGS Suite Expands Clonality and MRD Research in Lymphoid Malignancies
Lymphoid malignancies require molecular tools that can distinguish clonal immune receptor rearrangements and track disease-related sequences over time. As immune receptor measurable residual disease analysis... Read more
Tumor-Informed ctDNA Test Shows Utility Across Gastrointestinal and Gynecologic Cancers
Natera announced new data on Signatera, its tumor-informed circulating tumor DNA test, that were presented in four oral presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.... Read moreHematology
view channel
New Donor Genetic Marker May Help Predict Stem Cell Transplant Success
Donor selection for hematopoietic stem cell transplantation plays a major role in relapse risk and survival for patients with blood cancers and other blood disorders. Despite advances in genotyping, uncertainty... Read more
Updated Ferritin Thresholds Improve Detection of Iron Deficiency
Iron deficiency is one of the most common health conditions worldwide, yet its nonspecific symptoms can delay diagnosis for months. Variation in testing practices and ferritin thresholds may contribute... Read moreImmunology
view channel
Prototype Point-of-Care Test Aims to Improve Neonatal Sepsis Diagnosis
Neonatal sepsis remains difficult to diagnose because early signs can resemble other newborn conditions. Diagnostic delays may increase the risk of complications, death, long-term adverse outcomes, and... Read more
Single-Tier Lyme Disease Test Shows High Sensitivity in Early Infection
Lyme disease can be difficult to diagnose during the earliest stages of infection, when conventional serologic testing may have limited sensitivity. Patients may present during a diagnostic gray zone in... Read moreMicrobiology
view channel
Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis
Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more
Nanodroplet CRISPR Technology Supports Rapid, Multiplexed Mycobacterial Identification
Mycobacterial infections are difficult to diagnose because closely related species can have different clinical and therapeutic implications. Nontuberculous mycobacteria (NTM) are increasingly recognized... Read more
Genomic Workflow Identifies Fungal Pathogens Before Blood Cultures Turn Positive
Fungal bloodstream infections pose a major threat to hospitalized patients. Candida species cause most invasive fungal infections worldwide and are among the leading causes of hospital-acquired bloodstream... Read more
FDA-Cleared Multiplex PCR Test Detects 13 Respiratory Pathogens in a Single Sample
Respiratory tract infections can be difficult to distinguish at presentation because many cause overlapping, nonspecific symptoms and are initially grouped as influenza-like illnesses. Causes span a range... Read morePathology
view channel
Rapid Mass Spectrometry Test May Aid Glioma Margin Decisions
Glioma brain tumors are highly infiltrative and can extend into nearby healthy brain tissue, making tumor margins difficult to define during surgery. Residual tumor cells may contribute to recurrence and... Read more
Genomic Classifier Predicts Benefit From Adding Hormone Therapy to Salvage Prostate Radiation
Men who have undergone prostatectomy for prostate cancer may later develop a detectable or rising prostate-specific antigen, prompting salvage radiation therapy. A key challenge is determining who is most... Read moreTechnology
view channelLaser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns
Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more
Laser-Enhanced Assay Boosts Sensitivity for Colorectal Cancer Biomarker Detection
Colorectal cancer is the third most commonly diagnosed cancer and the second leading cause of cancer-related death worldwide. Early detection remains critical, but cancer biomarkers can produce only faint... Read moreIndustry
view channel
Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China
Quanterix Corporation (Billerica, MA, USA) and Innovita Biological Technology Co., Ltd. (Beijing, China) announced regulatory approvals that expand access to Quanterix SIMOA technology and neurology biomarker... Read more
Collaboration Advances Automated Benchtop Platform for Routine Blood Testing
Routine blood testing is central to clinical decision-making, but access can vary across laboratory and healthcare settings. Broader use of automated benchtop platforms may help integrate testing more... Read more
Expanded Partnership Supports AI Biomarker Validation and Clinical Trial Deployment
CellCarta (Montreal, Canada) and Imagene AI (Miami, FL, USA) have expanded their collaboration to provide biopharma companies with a coordinated pathway for biomarker strategy, assay development, validation,... Read more







